| Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis LR Soares, M Vilbert, VDL Rosa, JL Oliveira, MM Deus, R Freitas-Junior ESMO open 8 (4), 101613, 2023 | 16 | 2023 |
| Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis JN Priantti, M Vilbert, T Madeira, FCA Moraes, ECK Hein, A Saeed, ... Cancers 15 (15), 3754, 2023 | 11 | 2023 |
| Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: real-world experience from a Canadian Comprehensive Cancer Centre EC Koch Hein, M Vilbert, I Hirsch, M Fernando Ribeiro, TP Muniz, ... Cancers 15 (17), 4312, 2023 | 6 | 2023 |
| Cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone for HR-positive, HER-2-negative early breast cancer: meta-analysis of phase III … FCA Moraes, G de Oliveira Almeida, VFC Alves, JN Priantti, GC Gomes, ... Journal of Personalized Medicine 14 (5), 464, 2024 | 5 | 2024 |
| COVID-19 outcomes in patients with sickle cell disease and sickle cell trait compared with individuals without sickle cell disease or trait: a systematic review and meta-analysis I Michelon, M Vilbert, IS Pinheiro, IL Costa, CF Lorea, M Castonguay, ... EClinicalMedicine 66, 2023 | 5 | 2023 |
| Comparison of enzalutamide versus abiraterone in castration-resistant prostate cancer before docetaxel: Results of a propensity score-matched analysis. MG Cesca, MT Silveira, NC Pandolfi, TB Oliveira, JA Rinck, ... Journal of Clinical Oncology 37 (15_suppl), e16540-e16540, 2019 | 5 | 2019 |
| Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis I Michelon, M Vilbert, AD Marinho, CER Castro, MI Dacoregio, C Stecca, ... ESMO open 9 (2), 102233, 2024 | 4 | 2024 |
| SLAM modification as an immune-modulatory therapeutic approach in cancer A Tojjari, FJ Giles, M Vilbert, A Saeed, L Cavalcante Cancers 15 (19), 4808, 2023 | 3 | 2023 |
| Optimal Therapeutic Strategy for PD-L1 Negative Metastatic Non-Small Cell Lung Cancer: A Decision-Making Guide Based on Clinicopathological and Molecular Features M Malvicini, MS Vilbert, JN Minatta, VC Costas, MM Rizzo Current Treatment Options in Oncology 24 (11), 1550-1567, 2023 | 2 | 2023 |
| Customized autoantibodies (autoAbs) profiling to predict and monitor immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICI). S Genta, S Keshavarzi, N Yee, A Heirali, AR Hansen, LL Siu, S Saibil, ... Journal of Clinical Oncology 40 (16_suppl), 2528-2528, 2022 | 2 | 2022 |
| Neurocognitive adverse events related to lorlatinib in non-small cell lung cancer: a systematic review and meta-analysis JN Priantti, M Vilbert, FCA de Moraes, T Madeira, EM de Lima Santiago, ... Cancers 16 (14), 2024 | 1 | 2024 |
| Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis. J N. Priantti, M Vilbert, FCA Moraes, I Michelon, C Castro, NB Leighl, ... Journal of Clinical Oncology 42 (16_suppl), 8642-8642, 2024 | 1 | 2024 |
| Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma. M Vilbert, JN Priantti, T Madeira, FCA Moraes, A Tojjari, IH Sahin, ... Journal of Clinical Oncology 42 (3_suppl), 366-366, 2024 | 1 | 2024 |
| 1098P Anti-PD1-based neoadjuvant therapy in resectable stage III or IV melanoma patients: A systematic review and meta-analysis TM Madeira, FCA Moraes, JN Priantti, EM de Lima Santiago, MF Ribeiro, ... Annals of Oncology 34, S661, 2023 | 1 | 2023 |
| 1365P Neurocognitive adverse events related to lorlatinib in non-small cell lung cancer: A systematic review and meta-analysis JN Priantti, FCA Moraes, TM Madeira, EM de Lima Santiago, MS Vilbert Annals of Oncology 34, S784, 2023 | 1 | 2023 |
| Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to Immunotherapy M Vilbert, EC Koch, AAN Rose, RC Laister, D Gray, V Sotov, S Penny, ... Cancers 15 (14), 3708, 2023 | 1 | 2023 |
| Retreatment with EGFR inhibitor in non-small cell lung cancer patients previously exposed to EGFR-TKI: A systematic review and meta-analysis. I Michelon, M Vilbert, C Castro, C Stecca, MI Dacoregio, MM Rizzo, ... Journal of Clinical Oncology 41 (16_suppl), e21159-e21159, 2023 | 1 | 2023 |
| 220P Oral selective estrogen receptor degraders for metastatic hormone receptor-positive, HER2 negative breast cancer according to ESR1 mutation: A systematic review and meta … RGS Novello, M Lobo, MS Vilbert, SM Sanches, MG Cesca ESMO Open 8 (1), 2023 | 1 | 2023 |
| 834P Intracranial disease control and survival in patients with melanoma brain metastases (MBM) treated with radiation and immune checkpoint inhibitors (IO) MFSA Ribeiro, TP Muniz, P Jablonska, I Hirsch, M Vilbert, EC Koch, ... Annals of Oncology 33, S930, 2022 | 1 | 2022 |
| 831P outcomes of immune checkpoint inhibitors in patients with metastatic uveal melanoma treated with tebentafusp EC Koch, DPA Ceballos, M Vilbert, K Lajkosz, TP Muniz, I Hirsch, ... Annals of Oncology 33, S928, 2022 | 1 | 2022 |
